In light of the announcement made by the company this past Friday, it could be a good idea for investors to keep an eye on the Blue Star Opportunities Corp. (OTC:BSTO) stock. The company had come into sharp focus on April 12 after it announced that it had completed an agreement with YouBeNow, the Canadian artificial intelligence technology firm, Diomedes Inc., the medical intelligence company, and a consortium of those companies’s associates. Through the agreement, Blue Star Opportunities Corp. would complete the acquisition of MedGuard AI, the artificial intelligence-backed clinical management system.
In this regard, it should be noted that MedGuard AI was created so as to provide people with protection against prescription medication errors. Such errors are one of the major causes of mortality and morbidity in Western Europe and North America. Additionally, the acquisition also heralded a significant move from the company towards a new venture in the artificial intelligence, clinical analytics, and intelligence space. MedGuard AI operates as a personal medical advisory service offered online with the aim of serving individuals suffering from sports or medical-related conditions. The service helps the individuals monitor the quality of care that they receive.
The clinical workflow and the intelligence deployed by the system originated from early artificial intelligence systems that had been in use in tertiary care hospitals. Following the agreement, Blue Star Opportunities Corp. would be responsible for the commercial exploitation and deployment of the system. In this context, it should be noted that YouBeNow would be responsible for carrying on with providing technology and software support to the company. Additionally, it would also continue to work on providing new artificial intelligence-powered health-related applications. The agreement was also a validation of the change in direction that had been announced by Blue Star Opportunities Corp. in 2023.
 Stock Soars 35% After Acquisition News){kind=link}